Tung H. Bui
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Osteopontin is a therapeutic target that drives breast cancer recurrence.
Journal: Nature communications
Published: April 05, 2024
The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer.
Journal: Immunity
Published: March 23, 2023
Exploiting Mouse Models to Recapitulate Clinical Tumor Dormancy and Recurrence in Breast Cancer.
Journal: Endocrinology
Published: March 03, 2022
Emergence of β1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvironment.
Journal: Oncogene
Published: May 20, 2021
Functional Redundancy between β1 and β3 Integrin in Activating the IR/Akt/mTORC1 Signaling Axis to Promote ErbB2-Driven Breast Cancer.
Journal: Cell reports
Published: January 23, 2019
Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program.
Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program.
Journal: Nature communications
Published: March 20, 2017
β-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 18, 2017
Sulfur mass-independent fractionation in subsurface fracture waters indicates a long-standing sulfur cycle in Precambrian rocks.
Journal: Nature communications
Published: April 03, 2016
β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.
Journal: Cancer research
Published: May 31, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026